- Home
- CCII vs KMDA Comparison
CCII vs KMDA Comparison
Compare CCII & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCII
- KMDA
- Stock Information
- Founded
- CCII 2024
- KMDA 1990
- Country
- CCII United States
- KMDA Israel
- Employees
- CCII N/A
- KMDA N/A
- Industry
- CCII
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CCII
- KMDA Health Care
- Exchange
- CCII Nasdaq
- KMDA Nasdaq
- Market Cap
- CCII 350.7M
- KMDA 410.6M
- IPO Year
- CCII 2025
- KMDA N/A
- Fundamental
- Price
- CCII $10.17
- KMDA $6.70
- Analyst Decision
- CCII
- KMDA Strong Buy
- Analyst Count
- CCII 0
- KMDA 2
- Target Price
- CCII N/A
- KMDA $13.00
- AVG Volume (30 Days)
- CCII 134.2K
- KMDA 51.3K
- Earning Date
- CCII 01-01-0001
- KMDA 11-12-2025
- Dividend Yield
- CCII N/A
- KMDA 2.99%
- EPS Growth
- CCII N/A
- KMDA 27.97
- EPS
- CCII N/A
- KMDA 0.32
- Revenue
- CCII N/A
- KMDA $169,517,000.00
- Revenue This Year
- CCII N/A
- KMDA $14.49
- Revenue Next Year
- CCII N/A
- KMDA $10.12
- P/E Ratio
- CCII N/A
- KMDA $20.86
- Revenue Growth
- CCII N/A
- KMDA 9.67
- 52 Week Low
- CCII $10.07
- KMDA $5.17
- 52 Week High
- CCII $10.20
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- CCII N/A
- KMDA 40.07
- Support Level
- CCII N/A
- KMDA $6.76
- Resistance Level
- CCII N/A
- KMDA $6.89
- Average True Range (ATR)
- CCII 0.00
- KMDA 0.15
- MACD
- CCII 0.00
- KMDA -0.00
- Stochastic Oscillator
- CCII 0.00
- KMDA 30.61
About CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares
Cohen Circle Acquisition Corp II is a blank check company.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.